Analysts at Cowen began coverage on shares of Legend Biotech (NASDAQ:PLRX) in a note issued to investors on Monday, Marketbeat.com reports. The brokerage set an “outperform” rating on the stock.
A number of other equities analysts have also recently commented on the company. Piper Sandler initiated coverage on Legend Biotech in a report on Monday. They set an “overweight” rating and a $50.00 target price for the company. Citigroup initiated coverage on Legend Biotech in a report on Monday. They set a “buy” rating and a $40.00 target price for the company. Finally, Needham & Company LLC initiated coverage on Legend Biotech in a report on Monday. They set a “buy” rating and a $40.00 target price for the company.
NASDAQ PLRX opened at $32.46 on Monday. Legend Biotech has a twelve month low of $21.05 and a twelve month high of $35.63.
Pliant Therapeutics, Inc, a biotechnology company, discovers, develops, and commercializes treatments for fibrotic diseases. The company focuses on tissue-specific integrin modulation and EMT inhibition fibrosis diseases in lungs, liver, muscle, kidney, skin, heart, and the gastrointestinal tract. Its pipeline includes PLN-74809, an inhibitor of aVß1/aVß6 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis; and PLN-1474, an inhibitor of TGF-ß activation by the integrin aVß1 for the treatment of end-stage liver fibrosis in NASH.
Further Reading: What does an equal weight rating mean?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.